Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug AZD2389 targets scarred livers in tiny early trial

NCT ID NCT07069725

Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jul 28, 2026 · Updated 5 times

Summary

This early study tests whether a single dose of the experimental drug AZD2389 can attach to a protein called FAP in the liver. Twelve adults with advanced liver scarring (fibrosis) will get a PET scan before and after taking the drug to see if it binds to its target. The goal is not to treat the disease yet, but to learn if the drug works as designed in the body.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AZD2389
What this could lead to
If successful, this could show that AZD2389 reaches its target in the liver, supporting further development as a potential treatment for liver fibrosis.
What could go wrong
This is a very early, small study with only 12 participants. It only measures drug binding, not whether the drug improves liver health. Many early-stage drugs fail to show benefit in larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

8 people

The number who actually took part.

Started

May 2025

Finished

Jul 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: 1. Male or female (of non-childbearing potential) participant aged ≥ 20 years and willing and able to give written informed consent for participation in the trial. 2. History confirming compensated liver cirrhosis. 3. Females must have a negative pregnancy test. 4. Barrier contraceptives use by males. Key Exclusion Criteria: 1. A condition that would interfere with evaluation of the trial intervention, put the participant at risk, influence the participant's ability to participate or affect the interpretation of the results of the trial. 2. Any clinically significant illness, medical or major surgical procedure or trauma prior randomization. 3. Hepatitis B , hepatitis C and/or HIV infection. 4. Significant elevations in liver blood test, MELD score \>12 and platelets \<100 x109/L g). 5. eGFR) \< 60 ml/min/1.73m2. 6. History of decompensated liver cirrhosis. 7. Any participants with an aetiology of liver cirrhosis where the Investigator considers that PET signal uptake may be impacted. 8. History of bleeding disorders and major bleeding risk. 9. History of severe dermatological disorders or wound healing. 10. Positive screening result for drugs of abuse or alcohol.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hepatic cirrhosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cirrhosis of liver fibrotic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hepatic cirrhosis Liver fibrosis

Contacts and locations

Locations

  • Research Site

    Stockholm, 17176, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.